Nuclide Therapeutics
ID: 17900660Nuclide Therapeutics is a developer of targeted radiopharmaceuticals for therapy-resistant cancers founded in 2024 by Muhammet Tanc, Richard Edwards, Tim Witney and Sofia Santos.
1
Funding Rounds
$6.7m
Money raised
Recent Funding Rounds
Overview
Nuclide Therapeutics is a developer of targeted radiopharmaceuticals for therapy-resistant cancers founded in 2024 by Muhammet Tanc, Richard Edwards, Tim Witney and Sofia Santos.
- Website:
- Headquarters: London
- Social accounts: linkedin
Unlock Complete Company Intelligence
Access comprehensive data and insights available only to Seedtable members
Financial Details
- • Complete funding history and valuations
- • Revenue estimates and financial metrics
- • Investment round details and terms
People & Contacts
- • Complete leadership team profiles
- • Contact information and email addresses
- • Board members and advisors
Market Intelligence
- • Competitive landscape analysis
- • Market position and growth metrics
- • Industry benchmarking data
Premium Tools
- • Export data and generate reports
- • Save companies to custom watchlists
- • API access for data integration
Join 10,000+ Professionals
Trusted by investors, founders, and analysts worldwide
Access detailed insights on 71,000+ companies worldwide
| Name | Phone | Social networks | |
|---|---|---|---|
| Mu****** Ta** |
|
- | |
| Ri***** Ed***** |
|
- | |
| Ti* Wi**** |
|
- | |
| So*** Sa**** |
|
- |
Funding series
Funding Series Analysis
The company Nuclide Therapeutics has raised a total of $6.7m in funding over 1 rounds.
Key Insights:
- Nuclide Therapeutics Seed Round, September 2025: $6.7m
Industries
Nuclide Therapeutics is active in the following industries: